CompletedNot Applicable

Intravitreal Bevacizumab for the Treatment of CNV in VKH Disease - A Prospective Study

Brazil9 participantsStarted 2012-09

Plain-language summary

Efficacy of monthly intravitreal anti-vascular endothelial growth factor (VEGF) associated to systemic immunosuppression in patients with Vogt-Koyanagi-Harada Disease and choroidal neovascularization. Minimum follow-up 12 months. Endpoints: 6 and 12 months of follow-up. Outcome measures: improvement of VA, decrease in central foveal thickness as measured by Optical Coherence Tomography (OCT) and absence of intra/subretinal fluid.

Who can participate

Age range10 Years – 70 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Patients diagnosed with Vogt-Koyanagi-Harada disease based on Revised Diagnostic Criteria presented by the International Committee on VKH disease in 2001;
✓. Presence of choroidal neovascularization identified by fundus biomicroscopy, fluorescein angiography and OCT.

What they're measuring

Visual Acuity change

Timeframe: 6 months

Change in central foveal thickness

Timeframe: 6 months

Presence or absence of intra/subretinal fluid in OCT

Timeframe: 6 months

Trial details

NCT IDNCT02015351

SponsorUniversity of Sao Paulo

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2017-10

View on ClinicalTrials.gov More Choroidal Neovascularization trials